GCS GU 2018

Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes

Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes

By

In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.

Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups

By

Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.

Ramucirumab Plus Docetaxel May Improve QoL in Urothelial Carcinoma

Ramucirumab Plus Docetaxel May Improve QoL in Urothelial Carcinoma

By

The impact of this treatment on quality of life was not previously reported.

Cabozantinib May Improve Survival in mCRPC Patient Subgroup

Cabozantinib May Improve Survival in mCRPC Patient Subgroup

By

COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.

Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer

Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer

By

It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.

Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer

Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer

By

Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.

5-FU/Cisplatin, Gemcitabine May Be Effective Options for Invasive Bladder Cancer

5-FU/Cisplatin, Gemcitabine May Be Effective Options for Invasive Bladder Cancer

By

This study was designed to evaluate the efficacy of each treatment using 3-year distant metastasis-free survival as a primary outcome.

Papillary Renal Cell Carcinomas May Respond to Crizotinib

Papillary Renal Cell Carcinomas May Respond to Crizotinib

By

Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.

Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs

Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs

By

Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.

Pembrolizumab Improves OS, ORR After 2 Years vs Chemotherapy in Urothelial Cancer

Pembrolizumab Improves OS, ORR After 2 Years vs Chemotherapy in Urothelial Cancer

By

Of 542 enrolled patients, 270 were randomly assigned to pembrolizumab and 272 were assigned to chemotherapy. All patients progressed after platinum therapy.

Adjuvant Chemotherapy May Be New Standard of Care for Upper Tract Urothelial Cancer

Adjuvant Chemotherapy May Be New Standard of Care for Upper Tract Urothelial Cancer

By

The median follow-up was 17.6 months at time of interim analysis.

Nivolumab Monotherapy May Yield 8% Complete Response Rate in Urothelial Carcinoma

Nivolumab Monotherapy May Yield 8% Complete Response Rate in Urothelial Carcinoma

By

Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.

Enzalutamide Reduces Risk of Metastasis in Castration-Resistant Prostate Cancer

Enzalutamide Reduces Risk of Metastasis in Castration-Resistant Prostate Cancer

By

Researchers randomly assigned 1401 men with M0 CRPC undergoing ADT to receive enzalutamide 160 mg or placebo.

Comparing Daily vs Weekly Image-Guided Radiotherapy for Prostate Cancer

Comparing Daily vs Weekly Image-Guided Radiotherapy for Prostate Cancer

By

It is unestablished whether daily or weekly IGRT is optimal for patients with N0 localized prostate cancer.

Prostate Cancer: Adding Zoledronate to Androgen Suppression and Radiotherapy Not Beneficial

Prostate Cancer: Adding Zoledronate to Androgen Suppression and Radiotherapy Not Beneficial

By

A significant reduction in prostate cancer-specific mortality — the primary outcome — was observed among patients who received 18 months of AS.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs